Stereotactic ablative radiotherapy (SABR) for patients with metachronous extracranial oligometastatic cancer (all ages)

Document first published:: 6 March 2020
Page updated:: 17 September 2021
Topic:: Specialised commissioning
Publication type:: Policy or strategy

SABR will be available as a treatment option through routine commissioning for patients (all ages) with controlled primary cancer presenting with up to three extracranial metachronous oligometastases which manifest after a disease-free interval following primary treatment of at least 6 months, in line with the criteria set out in this document.